Dr. Murphy on Remaining Questions With SBRT in Pediatric Sarcoma

Erin Murphy, MD, radiation oncologist, Cleveland Clinic, discusses remaining questions with stereotactic body radiotherapy (SBRT) in pediatric sarcoma.

Findings from a retrospective study of 10 heavily pretreated pediatric patients with metastatic sarcoma showed that combining pazopanib (Votrient) with SBRT was safe and tolerable.

However, additional research is required to determine the optimal dose of SBRT in this patient population, as well as to identify contributing factors to local control vs failure with SBRT, says Murphy. The current guidelines for utilizing SBRT in patients with pediatric sarcoma are limited, and dosing should likely be individualized based on histology and lesion, concludes Murphy.